{
  "id": 10700301,
  "title": "Nike Is Down Nearly 50%, and Wall Street Analysts Keep Downgrading It. Here's Why History Says They're Missing the Bigger Picture.",
  "url": "https://urgent.news/2026/09/29/nike-is-down-nearly-50-and-wall-street-analysts-keep-downgrading-it",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-29T13:13:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/09/29/nike-is-down-and-wall-street-analysts-keep-down/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "When examining Nike's (NYSE: NKE) stock chart today, it's impossible to ignore the distressing decline. Financial analysts and social media users have been harsh critics, and with good reason. The stock has plummeted around 48% over the past year and more than 40% year-to-date, hovering near levels last seen a decade ago. Major banks like Bank of America and JPMorgan have downgraded Nike, issuing negative price targets. At first glance, the outlook appears bleak. However, a closer look at Nike's history reveals a resilient company that has weathered challenging cycles and continued to reward long-term shareholders.\n\nWall Street's recent concerns are not unfounded. Nike has projected near-term revenue declines, projecting a 2% to 4% drop in the current quarter and low-single-digit growth for the remainder of fiscal 2026. China's market, a significant revenue driver, is expected to contract roughly 20% in the quarter. JPMorgan recently downgraded Nike to Neutral and then Underweight, warning that the company's \"Win Now\" initiatives might squeeze margins before they can generate lasting benefits.",
  "summary": "Nike has taken a beating, but its latest slump could look very different.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.",
        "url": "https://urgent.news/2026/09/29/2-wall-street-analysts-think-vertex-pharmaceuticals-stock-can-soar",
        "published": "2026-09-29T09:10:00.000Z"
      },
      {
        "outlet": "Nasdaq Markets",
        "title": "2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.",
        "url": "https://urgent.news/2026/09/29/2-wall-street-analysts-think-vertex-pharmaceuticals-stock-can-soar-10663223",
        "published": "2026-09-29T09:30:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}